Association Between Patient-Reported Pain and Remission or Low Disease Activity in Patients with Rheumatoid Arthritis: Data from RA-BE-REAL Prospective Observational Study by Peter C. Taylor, Walid Fakhouri, Samuel Ogwu, Ewa Haladyj, Inmaculada de la Torre, Bruno Fautrel, Rieke Alten, Peter Nash, Eugen Feist

Get full text

What benefit–risk trade-offs are acceptable to rheumatoid arthritis patients during treatment selection? Evidence from a multicountry choice experiment by Carlomaurizio Montecucco, Rieke Alten, Robert Moots, Peggy Jacques, Helga Radner, Harald E Vonkeman, Nicolas Krucien, Sebastian Heidenreich, Katrien Van Beneden, Juan Carlos Nieto-González, Chiara Whichello

Get full text

Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to we... by Goran Babic, Hideto Kameda, Rieke Alten, Bogdan Batko, Tomas Hala, Sebastiao C Radominski, Vira Tseluyko, Carol Cronenberger, Sarah Hackley, Muhammad Rehman, Oliver von Richter, Min Zhang, Stanley Cohen

Get full text

Impact of filgotinib on pain control in the phase 3 FINCH studies by Bruno Fautrel, Peter Nash, Arthur Kavanaugh, Peter C Taylor, René Westhovens, Rieke Alten, Janet Pope, Dick de Vries, Chris Watson, Georg Pongratz, Pieter-Jan Stiers, Ken Hasegawa, Shangbang Rao

Get full text

Predicting abatacept retention using machine learning by Rieke Alten, Claire Behar, Pierre Merckaert, Ebenezer Afari, Virginie Vannier-Moreau, Anael Ohayon, Sean E. Connolly, Aurélie Najm, Pierre-Antoine Juge, Gengyuan Liu, Angshu Rai, Yedid Elbez, Karissa Lozenski

Get full text